Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The reduced folate transporter (RFC), also known as SLC19A1, is a ubiquitously expressed membrane protein that serves as the primary transporter for reduced folates in mammalian cells and tissues. It functions as an antiporter, mediating the import of reduced folates and cyclic dinucleotides in exchange for organic anions. RFC plays a crucial role in cellular folate uptake, essential for one-carbon metabolism. It is also a key mediator of antifolate drug uptake, making it clinically relevant in cancer chemotherapy and drug resistance.
RFC mediates the cellular uptake of antifolate drugs like methotrexate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Reduced Folate Transporter (RFC).